Table 2.
Progression-Free and Overall Survival According to Radiological Response and STM Response in the Respective Treatment Phases
| Chemo-Immunotherapy | n | Median PFS (M, 95% CI) | p | Median OS (M, 95% CI) | P | |
|---|---|---|---|---|---|---|
| CT response (RECIST) | PR | 31 | 13 (9,/) | <0.001 | n.r. (15,/) | 0.01 |
| SD | 28 | 5 (4,7) | n.r. (5,/) | |||
| PD | 14 | 3 (2,5) | 6 (3,10) | |||
| STM response | Decrease | 41 | 9 (5,12) | 0.042 | 15 (10,/) | 0.363 |
| Increase | 16 | 5 (3,6) | n.r. (10,/) | |||
| Mono-immunotherapy | n | Median PFS (95% CI) | p | Median OS (95% CI) | P | |
| CT response (RECIST) | CR/PR | 9 | n.r. (8,/) | <0.001 | n.r. (/,/) | 0.009 |
| SD | 24 | 7 (4,16) | n.r. (7,/) | |||
| PD | 17 | 2 (1,3) | 7 (2,/) | |||
| STM response | Decrease | 16 | 16 (7,/) | <0.001 | n.r. (/,/) | 0.055 |
| Increase | 22 | 3.5 (2,6) | n.r. (7,/) | |||
Notes: Data are given as time in months (95% confidence interval). Testing for significance between the subgroups was accomplished using a Log rank test, a p value of <0.05 was regarded statistically significant. Missing figures (/) are for values non assessable.
Abbreviations: PFS, progression-free survival; OS, overall survival; M, months; CI, confidence interval; CT, computed tomography; RECIST, response evaluation criteria in solid tumors; STM, serum tumor marker; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.